Home  /  Resource Library  /  Cost-effectiveness of HLX01 (Hanlikang) vs. rituximab combined with CHOP in treatment-naive diffuse large B-Cell lymphoma: a partitioned survival model analysis

Cost-effectiveness of HLX01 (Hanlikang) vs. rituximab combined with CHOP in treatment-naive diffuse large B-Cell lymphoma: a partitioned survival model analysis

Study examined the cost effectiveness of rituximab biosimilar Hanlikang for treatment of DLBCL.